Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: =99.39%
Mirabegron (formerly YM-178; YM178; Myrbetriq; Betanis; Betmiga) is a potent and selective β3-adrenoceptor agonist with similar effects to antimuscarinic medications. It stimulates the β3-adrenoceptor with an EC50 of 22.4 nM. The medication mirabegron is authorized for the management of overactive bladder. When the β3 adrenergic receptor in the bladder's detrusor muscle is activated by mirabegron, the muscle relaxes and the bladder's capacity increases.
Targets |
β3-adrenoceptor ( EC50 = 22.4 nM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
In every well of a 24-well culture plate, 105 CHO cells are deposited and allowed to grow. A pH 7.4 Hanks balanced salt solution containing 0.1 mM 3-isobutyl-1-methylxanthine is added to each well of the medium three days later. 250 μL of 0.2 M HCl is added to end the incubation of the cells after they have been exposed to each compound (isoproterenol, Mirabegron, BRL37344, and CL316,243) for 10 minutes at 37°C. The compounds are added at final concentrations of 10-10 to 10- M. Through radioimmunoassay with a 125I-cAMP assay system and a gamma counter, the concentration of cAMP in the reaction mixture is determined. The reaction is stopped by adding 400 μL of buffer solution after 50 microliters of reaction mixture and 50 μL of succinyl agent are incubated for 10 minutes at room temperature. For 24 hours at 4°C, 50 microliters of succinylated sample are incubated with 50 μL of 125I-cAMP and 50 μL of anti-cAMP antibody. After the incubation period, add 250 μL of charcoal suspension, and centrifuge at 2800g for 10 minutes at 4°C. After being transferred into a tube, 250 microliters of supernatant are counted for one minute using a gamma counter. The maximal response of each compound is used to calculate the intrinsic activity (I.A.) relative to isoproterenol for each β-adrenoceptor agonist.
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C21H24N4O2S
|
|
---|---|---|
Molecular Weight |
396.51
|
|
Exact Mass |
396.16
|
|
Elemental Analysis |
C, 63.61; H, 6.10; N, 14.13; O, 8.07; S, 8.09
|
|
CAS # |
223673-61-8
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
|
|
InChi Key |
PBAPPPCECJKMCM-IBGZPJMESA-N
|
|
InChi Code |
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
|
|
Chemical Name |
2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5220 mL | 12.6100 mL | 25.2200 mL | |
5 mM | 0.5044 mL | 2.5220 mL | 5.0440 mL | |
10 mM | 0.2522 mL | 1.2610 mL | 2.5220 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06181019 | Active Recruiting |
Drug: 50 mg of mirabegron Combination Product: acupuncture combined with mirabegron |
Overactive Bladder | The Affiliated Ganzhou Hospital of Nanchang University |
December 1, 2021 | Phase 1 |
NCT05745584 | Active Recruiting |
Drug: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics |
Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics |
Yonsei University | January 12, 2016 | Not Applicable |
NCT06011265 | Active Recruiting |
Drug: Myrbetriq 25Mg Extended -Release Tablet Drug: Placebo |
Thermoregulation | Christopher Bell | April 27, 2023 | Early Phase 1 |
NCT05779514 | Recruiting | Drug: Mirabegron | Tumour | Zhejiang Provincial People's Hospital |
August 18, 2022 | Not Applicable |
NCT05051436 | Recruiting | Drug: Mirabegron 50 MG Drug: Tadalafil 10 MG Drug: Placebo |
Pre-diabetes Obesity |
Philip Kern | December 13, 2021 | Phase 4 |